Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00534378 · ClinicalTrials.gov registry record · Phase 1

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

A Phase 1 study of Seizures, sponsored by U.S. Army Office of the Surgeon General.

Completed
Registry status
Phase 1
Development phase
39
Enrollment target
1
Study location

NCT00534378: Completed Phase 1 study of Seizures, sponsored by U.S. Army Office of the Surgeon General.

NCT00534378 is a Phase 1 study of Seizures that has completed, run by U.S. Army Office of the Surgeon General. The registered enrollment target is 39 participants, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00534378, a Phase 1 study of Seizures, has completed, sponsored by U.S. Army Office of the Surgeon General.

COMPLETED
Registry status
Phase 1
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

Purpose of the study is to determine midazolam's safety and dose-linearity when delivered intramuscularly via an autoinjector. The proposed initial treatment dosage for seizures induced by exposure to nerve agents.

Conditions Studied

Interventions

  • DRUG Midazolam

Study Locations (1)

Maryland

  • BASi Baltimore Clinical Research Unit - Baltimore

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2006-07
Est. Completion 2006-12
Phase Phase 1

What the finished NCT00534378 record still lists

NCT00534378 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Seizures appearing as the primary indexed condition, and to 1 intervention - of which Midazolam is the first listed.

NCT00534378 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00534378 about?

NCT00534378 is a clinical study titled "Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector". Purpose of the study is to determine midazolam's safety and dose-linearity when delivered intramuscularly via an autoinjector. The proposed initial treatment dosage for seizures induced by exposure to nerve agents.

What is the current status of trial NCT00534378?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2006-07. Estimated completion is 2006-12.

What conditions does trial NCT00534378 study?

This clinical trial studies the following conditions: Seizures.

What interventions are being tested in trial NCT00534378?

The interventions under investigation include: Midazolam (DRUG).

Who is sponsoring clinical trial NCT00534378?

This trial is sponsored by U.S. Army Office of the Surgeon General, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00534378 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Seizures

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00534378's enrollment target sits among peer trials

39 28th of 39 higher than 11 of 39 other Seizures trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Seizures trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00534378, the US trial registry maintained by the National Library of Medicine. NCT00534378 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.